STOCK TITAN
  1. Home
  2. Sec-filings
  3. SLXN
  4. [Form 4] Silexion Therapeutics Corp Insider Trading Activity

Silexion (SLXN) CEO granted 10,000 shares; holdings rise to 16,547

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Silexion Therapeutics Corp reported that Chairman and CEO Hadar Ilan received a grant of 10,000 ordinary shares at no cost, delivered through fully vested restricted share units for services as an officer and approved by the board. After this award, Ilan directly holds 16,547 ordinary shares. The Form 4 also updates a stock option position to 96 options for 96 ordinary shares at an exercise price of $9,077.10 per share, reflecting a 1-for-10 reverse share split completed on May 28, 2026. The option holdings are shown for informational purposes, with no new option transactions reported.

Positive

  • None.

Negative

  • None.
Insider Hadar Ilan
Role Chairman and CEO
Type Security Shares Price Value
Grant/Award Ordinary Shares 10,000 $0.00 --
holding Stock Option (right to buy Ordinary Shares) -- -- --
Holdings After Transaction: Ordinary Shares — 16,547 shares (Direct, null); Stock Option (right to buy Ordinary Shares) — 96 shares (Direct, null)
Footnotes (1)
  1. The number of ordinary shares, par value $0.135 per share ("ordinary shares"), reported in this Form 4 reflects an adjustment relative to the Form 4 filed by the Reporting Person on February 23, 2026 due to the 1-for-10 reverse share split effected by the Issuer on May 28, 2026 (which caused the 65,471 ordinary shares, par value $0.0135, beneficially owned by the Reporting Person as reported in that Form 4 to become 6,547 ordinary shares, par value $0.135, prior to the grant reported in this Form 4). The transaction reported in this row consists of the grant to the Reporting Person by the Issuer of fully vested restricted share units (RSUs), which were immediately settled for underlying ordinary shares, in respect of the Reporting Person's services as an officer of the Issuer. The grant was approved by the Issuer's board of directors. There were no transactions effected in respect of the securities reported in this row, and the holdings in this row are being included for informational purposes only. The number of options to purchase ordinary shares and underlying ordinary shares, and the exercise price of the options, reported in this row have been adjusted to reflect the 1-for-10 reverse share split effected by the Issuer on May 28, 2026 (which caused the 956 options to purchase 956 ordinary shares, par value $0.0135, at an exercise price of $907.71 per share, beneficially owned by the Reporting Person as reported in that Form 4, to become 96 options to purchase 96 ordinary shares, par value $0.135, at an exercise price of $9,077.10 per share).
RSU grant shares 10,000 shares Fully vested RSUs immediately settled into ordinary shares
Shares held after grant 16,547 shares Ordinary shares directly held by Hadar Ilan after award
Reverse split ratio 1-for-10 Reverse share split effected on May 28, 2026
Pre-split shares 65,471 shares Ordinary shares beneficially owned before reverse split adjustment
Post-split base shares 6,547 shares Adjusted ordinary shares after 1-for-10 reverse split, before new grant
Options outstanding 96 options Stock options to buy 96 ordinary shares after reverse split adjustment
Option exercise price $9,077.10 per share Exercise price of adjusted stock options expiring March 24, 2032
Original options pre-split 956 options Options to purchase 956 ordinary shares before 1-for-10 reverse split
reverse share split financial
"due to the 1-for-10 reverse share split effected by the Issuer on May 28, 2026"
A reverse share split is when a company reduces the number of its shares outstanding by combining multiple shares into one, effectively increasing the price of each share. For investors, this can help improve the company's image or meet stock exchange listing requirements, but it does not change the total value of their investment. It’s similar to turning many small pieces of a puzzle into fewer larger pieces—nothing new is added or lost, just rearranged.
restricted share units (RSUs) financial
"fully vested restricted share units (RSUs), which were immediately settled for underlying ordinary shares"
Restricted share units (RSUs) are a form of employee pay where a company promises to give shares (or their cash value) to workers after certain conditions, usually time or performance, are met. For investors, RSUs matter because they can increase the number of shares outstanding and signal how management is being paid and incentivized—think of them as delayed bonuses that convert into ownership when vesting conditions are satisfied.
beneficially owned financial
"beneficially owned by the Reporting Person as reported in that Form 4"
Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.
exercise price financial
"at an exercise price of $9,077.10 per share"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
stock option financial
"Stock Option (right to buy Ordinary Shares)"
A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Hadar Ilan
(Last)(First)(Middle)
C/O SILEXION THERAPEUTICS CORP
12 ABBA HILLEL ROAD
(Street)
RAMAT GAN5250606
(City)(State)(Zip)
ISRAEL
(Country)		2. Issuer Name and Ticker or Trading Symbol
Silexion Therapeutics Corp [ SLXN ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
XOfficer (give title below)Other (specify below)
Chairman and CEO
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/04/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Ordinary Shares(1)06/04/2026A(2)10,000A$016,547D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (right to buy Ordinary Shares)(3)$9,077.1(4)08/15/202403/24/2032Ordinary Shares96(4)96(4)D
Explanation of Responses:
1. The number of ordinary shares, par value $0.135 per share ("ordinary shares"), reported in this Form 4 reflects an adjustment relative to the Form 4 filed by the Reporting Person on February 23, 2026 due to the 1-for-10 reverse share split effected by the Issuer on May 28, 2026 (which caused the 65,471 ordinary shares, par value $0.0135, beneficially owned by the Reporting Person as reported in that Form 4 to become 6,547 ordinary shares, par value $0.135, prior to the grant reported in this Form 4).
2. The transaction reported in this row consists of the grant to the Reporting Person by the Issuer of fully vested restricted share units (RSUs), which were immediately settled for underlying ordinary shares, in respect of the Reporting Person's services as an officer of the Issuer. The grant was approved by the Issuer's board of directors.
3. There were no transactions effected in respect of the securities reported in this row, and the holdings in this row are being included for informational purposes only.
4. The number of options to purchase ordinary shares and underlying ordinary shares, and the exercise price of the options, reported in this row have been adjusted to reflect the 1-for-10 reverse share split effected by the Issuer on May 28, 2026 (which caused the 956 options to purchase 956 ordinary shares, par value $0.0135, at an exercise price of $907.71 per share, beneficially owned by the Reporting Person as reported in that Form 4, to become 96 options to purchase 96 ordinary shares, par value $0.135, at an exercise price of $9,077.10 per share).
/s/ Mirit Horenshtein Hadar, Attorney-in-fact06/08/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Silexion Therapeutics (SLXN) report for Hadar Ilan?

Silexion reported that Chairman and CEO Hadar Ilan received 10,000 ordinary shares via fully vested RSUs, granted as compensation for services as an officer and approved by the board. This non-cash award increased Ilan’s direct holdings to 16,547 ordinary shares.

How many Silexion (SLXN) shares does Hadar Ilan hold after this Form 4 filing?

After the reported RSU grant, Hadar Ilan directly holds 16,547 ordinary shares of Silexion Therapeutics. This reflects the addition of 10,000 newly granted shares on top of 6,547 shares adjusted for the company’s 1-for-10 reverse share split completed on May 28, 2026.

What was the size and nature of the equity award to Silexion (SLXN) CEO Hadar Ilan?

Hadar Ilan received a grant of 10,000 ordinary shares through fully vested restricted share units that were immediately settled into shares. The award was approved by Silexion’s board of directors and compensates Ilan for services as an officer rather than an open-market share purchase.

How did Silexion’s reverse share split affect Hadar Ilan’s reported holdings?

Silexion completed a 1-for-10 reverse share split on May 28, 2026. This changed Ilan’s previously reported 65,471 ordinary shares into 6,547 shares and adjusted 956 options into 96 options. The Form 4 explains these adjustments and then adds the new 10,000-share RSU grant on top.

What stock options does Silexion (SLXN) CEO Hadar Ilan hold after this filing?

The filing shows Hadar Ilan holds 96 stock options, each for one ordinary share, with an exercise price of $9,077.10 per share and an expiration date of March 24, 2032. These option figures were adjusted to reflect Silexion’s 1-for-10 reverse share split on May 28, 2026.

Was the Silexion (SLXN) CEO’s 10,000-share grant an open-market purchase?

No. The 10,000 ordinary shares were granted as fully vested restricted share units that immediately settled into shares, with a reported price per share of $0.0000. The award reflects compensation for Hadar Ilan’s services as an officer, not an open-market stock purchase.